Supplementary Material 2. Modifications made to the protocol of therapy using *Karanahan* technology

I. Administration of the DNAmix preparation

1. Dose escalation of the DNAmix preparation from 1 to 12 mg

2. The preparation is administered not only intratumorally but also into the lymph depots (into inguinal lymph node clusters, axillary lymph nodes, and paraumbilically) (Figure S2).




Figure S2. Additional zones for administering the DNAmix preparation according to *Karanahan* technology

II. Detoxification measures taken during treatment using *Karanahan* technology

1. Switching the immunity to the anti-inflammatory status. Stimulation of the M2 immune response

Several (3–5) days before treatment initiation, two medications should be taken in an alternate manner:

Salmon sperm DNA 50 mg on day 1

Preparation based on extract of Ganoderma lucidum (b-glucans) 50 mg on day 2

Salmon sperm DNA 50 mg on day 3

Preparation based on extract of Ganoderma lucidum (b-glucans) 50 mg on day 4

Salmon sperm DNA 50 mg on day 5

The alternating regimen is important to prevent the development of drug tolerance in immune cells.

2. Prevention of capillary microthrombosis and development of the systemic immune response

Clexane® (low-molecular-weight heparin) 0.4 (0.4 mL syringe) once daily, subcutaneous injections into the abdomen starting day 2 after treatment initiation.

Infusion therapy S-NaCl 0.9% 1000 mL

3. Kidney protection

Torasemide ½ tablets twice daily.

S-NaHCO3 2%(4%) 200 mL

These measures are needed for preventing crystal formation in renal tubules and washing them (daily starting with day 2 after therapy initiation).

Acute period, 14 days.